Arsenic trioxide - Teva Pharmaceutical Industries

Drug Profile

Arsenic trioxide - Teva Pharmaceutical Industries

Alternative Names: NSC-706363; Trisenox

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CTI BioPharma
  • Developer Leukemia SPORE; Northwestern University; Temple University; Teva Pharmaceutical Industries; University of Texas M. D. Anderson Cancer Center
  • Class Anti-inflammatories; Antineoplastics; Arsenicals; Ischaemic heart disorder therapies; Oxides; Small molecules
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Acute promyelocytic leukaemia; Liver cancer; Multiple myeloma; Chronic myeloid leukaemia; Myelodysplastic syndromes; Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute promyelocytic leukaemia
  • Phase II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase I/II Glioma
  • Discontinued Multiple myeloma

Most Recent Events

  • 12 Sep 2017 Preregistration for Acute promyelocytic leukaemia (Combination therapy, Newly diagnosed) in USA (IV)
  • 12 Sep 2017 Arsenic trioxide receives priority review status for Acute promyelocytic leukaemia (Combination therapy, Newly diagnosed) in USA (IV)
  • 22 Nov 2016 Launched for Acute promyelocytic leukaemia (Combination therapy, Newly diagnosed) in Slovakia, Luxembourg, Lithuania, Latvia, Czech Republic, Poland, Belgium, Greece, Italy, Portugal, Spain, Finland, Denmark, Sweden, Austria, France, Ireland, Netherlands, United Kingdom and Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top